Table 3. Baseline and end‐point values of various parameters in the non‐pioglitazone (control) and pioglitazone groups.
| Control (n = 26) | Pioglitazone (n = 22) | |||
|---|---|---|---|---|
| Baseline | End‐point | Baseline | End‐point | |
| Weight (kg) | 73.4 ± 15.4 | 73.5 ± 15.5 | 70.5 ± 11.0 | 72.5 ± 12.4* |
| Blood pressure | ||||
| Systolic (mmHg) | 133.1 ± 13.7 | 136.5 ± 13.3 | 123.2 ± 13.0 | 132.4 ± 13.3 |
| Diastolic (mmHg) | 78.3 ± 11.1 | 77.8 ± 12.1 | 75.4 ± 10.3 | 76.6 ± 11.7 |
| Total daily insulin dose (U/day/kg) | 0.57 ± 0.23 | 0.59 ± 0.20 | 0.54 ± 0.31 | 0.50 ± 0.32‡ |
| Number of insulin injection (times/day) | 3.4 ± 0.8 | 3.5 ± 0.9 | 3.1 ± 0.6 | 2.9 ± 0.9‡ |
| HbA1c (%) | 8.64 ± 1.23 | 8.09 ± 1.39* | 8.59 ± 1.28 | 7.33 ± 0.86*‡ |
| Fasting serum glucose (mg/dL) | 185.2 ± 67.8 | 165.3 ± 51.5 | 184.1 ± 44.6 | 148.9 ± 44.0† |
| Fasting serum C‐peptide (ng/mL) | 1.64 ± 1.25 | 1.65 ± 1.03 | 1.61 ± 0.72 | 1.63 ± 0.66 |
| LDL cholesterol (mg/dL) | 129.6 ± 31.9 | 117.8 ± 26.5† | 125.0 ± 23.6 | 120.6 ± 19.5 |
| HDL cholesterol (mg/dL) | 50.3 ± 14.1 | 49.8 ± 14.2 | 51.8 ± 14.1 | 54.6 ± 14.1† |
| Triglycerides (mg/dL) | 162.4 ± 94.1 | 154.8 ± 95.9 | 157.9 ± 96.8 | 125.5 ± 50.9 |
| High sensitive‐CRP (mg/dL) | 0.160 ± 0.200 | 0.162 ± 0.169 | 0.098 ± 0.069 | 0.069 ± 0.045 |
| High‐molecular adiponectin (μg/mL) | 2.31 ± 2.20 | 2.11 ± 1.69 | 1.89 ± 1.71 | 4.44 ± 2.38*‡ |
| Intima‐media thickness (mm) | 0.923 ± 0.139 | 0.884 ± 0.140 | 0.927 ± 0.143 | 0.877 ± 0.127* |
*P < 0.01 vs baseline, †P < 0.05 vs baseline, ‡P < 0.05 vs control.